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Introduction: We conducted a double-blind randomised controlled trial in a remote-living Australian Aboriginal
group at high risk for chronic disease to assess whether pharmacological treatment with angiotensin converting
enzyme inhibitor (ACEi) could delay the onset of albuminuria, hypertension or diabetes in people currently free
of those conditions.
Methods: Eligibility criteria in 2008 were age ≥18yr, blood pressure ≤140/90 mm/Hg, urinary albumin
creatinine ratio (ACR) < 3.4mg/mmol, normal levels of glycosylated haemoglobin, and, in females, infertility.
A 2011 amendment allowed enrolment of fertile females using long-term contraception. “Treatment” was the
ACEi perindopril arginine, or placebo, and participant events were ACR ≥3.4 mg/mmol and/or blood pres-
sure> 140/90mm Hg and/or haemoglobin A1c> 6.5%, and/or cardiovascular events. Results were analysed in
125 randomised participants who commenced treatment.
Results: Recruitment was low, especially of women, and dropout rates high: there were finally 60 and 65 people
in the ACEi and placebo groups respectively. In females, there were no events among 10 in the ACEi group,
versus 5 events among 17 in the placebo group, and longitudinal ACR, HbA1c and blood pressure levels sup-
ported probable benefit of ACEi. There was no benefit of ACEi in males, but a probable benefit on diabetes/
hypertension events. With the genders combined, there was probable reduction of diabetes (zero vs 4 events,
p= 0.068), and of diabetes or hypertension (zero vs 5 events, p= 0.037).
Discussion: In this high-risk population, ACEi probably delays development of albuminuria, diabetes and hy-
pertension in females, and of non-ACR events overall. Repeat investigation with a larger sample size is war-
ranted.
1. Introduction
In a high-risk remote-living Aboriginal group, we implemented a
double-blind randomised controlled trial (RCT) to assess whether an-
giotensin converting enzyme inhibitor (ACEi) was effective in delaying
the onset of albuminuria, hypertension or diabetes among adults “free”
of these conditions.
Indigenous people in Australia have a high burden of chronic
disease, which is most marked in those who live in the remote regions
of the country [1–4]. It is characterised by hypertension, kidney disease
and type 2 diabetes which affect most of the population by middle age,
with high rates of heart attacks, strokes, amputations, blindness, and
kidney failure. Rates of hospitalizations for chronic diseases are very
high, kidney failure has reached epidemic proportions, and govern-
ments are straining to meet the spiralling costs of dialysis treatment
[5,6].
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We conducted two screens, in 1992–1996 and 2004–2006, in the
remote Tiwi, Aboriginal community, which both showed high rates
albuminuria, hypertension and diabetes in adults and remarkable in-
creases in rates with increasing age [7,8]. Among people who were free
of the specific markers on the first screen, the estimated incidence be-
tween the screens of any or all of the endpoints was between 5.5 and 11
per 100 person years, with the most common marker being new
onset albuminuria (unpublished data). We also showed, in a 3.5 year
treatment program from late 1995 to November 1999, that treatment of
subjects with albuminuria and hypertension with ACEi was associated
with significant reductions in blood pressure (BP), and in rates of renal
failure and all-cause natural deaths [9,10].
The high incidence of new-onset disease we observed, and the de-
monstrated benefit of treatment on existing disease, led us to question
whether treatment with ACEi could prevent or delay subsequent disease
onset in people who were, at a given point, disease free. We designed a
randomised controlled trial to test this hypothesis.
2. Materials and methods
2.1. Recruitment
Volunteers from the remote community were potentially eligible for
participation if they were≥18 years of age, had no documented history
of hypertension, diabetes or renal disease, and had BP≤ 140/90 mm/
Hg, urine albumin creatinine ratio (ACR) < 3.4mg/mmol, and no
diabetes on their most recent health check, and had no known con-
traindications to ACEi. A person was defined as diabetic if they had a
medical history of diabetes, HbA1c>6.5% and/or they met the WHO
criteria for diabetes on oral glucose challenge [11].
Reasons for exclusion included: a history of intolerance to ACEi; the
presence of other diseases with potential to interfere with or contra-
indicate treatment; psychosis, or emotional, or intellectual issues that
could invalidate informed consent or limit their ability to comply with
protocol requirements; and, being a female of childbearing potential
who was not using long-term contraception (sterilisation or a contra-
ceptive implant).
Approval for the trial was obtained in 2006 from the community's
Land Council and the Human Research Ethics Committees (HREC) of
the Northern Territory Department of Health and the Menzies School of
Health Research (06/34) and The University of Queensland
(2006000671). However, the original approval ruled that potentially
fertile women be excluded.
Beginning in June 2008, potentially eligible adult community
members were identified from community health centre records and
from results of the previous 2004–2006 community-wide chronic dis-
ease screening program [10].
Recruitment was delayed due to medicine supply problems, and
enrolment, with informed consent, finally began in November 2008. Of
923 identified people contacted for an eligibility interview, 530 (57%)
were deemed ineligible due to interim development of established
disease or status as a potentially fertile woman. Of the remaining 393,
21 (2%) had died, 85 (9%) refused and 67 (7%) could not be contacted.
Thus, only 220 (24%) appeared to be candidates for further eligibility
testing. Of these, 160 candidates (33 females and 127 males) were
found to be eligible and were subsequently enrolled.
Twenty-eight months into the trial, in February 2011, an ethics
amendment was approved to allow enrolment of fertile women who
were using long-term contraception. After a slow start, a further 9
women were enrolled between January and February 2012. A total
enrolment of 169 adults, 127 (75%) men and 42 women (25%), was
achieved.
2.2. Trial procedures
The intent was to randomise participants to the ACEi perindopril
arginine or an inactive, visually identical placebo. Both were supplied
by Servier. Participants were provided with 5mg tablets (or placebo),
and prescribed one tablet daily for the first month, then two tablets
(10mg) daily after one month and thereafter, where tolerated. If there
was suspicion that the drug was not being tolerated, or if a serious
adverse event occurred, treatment was immediately discontinued.
Administration of treatment, and collection of clinical measures and
pathology specimens according to the trial's protocol, occurred from
dedicated offices located near each of the Community's health centres.
The intended period of follow-up was 60 months with visits every 2
weeks for the first two months and monthly thereafter. Field staff
managed the timing of visits with flexibility, accommodating un-
planned events, as well as travel and weather disturbances. They also
provided transport of participants to and from the field offices.
At each visit, participants returned their unused tablets, if there
were any, at which time a count of tablets was recorded, returned ta-
blets were disposed of and next month's allocation was issued. A rea-
sonable degree of treatment adherence was considered to have occurred
if participants took, on average, at least 50% of each treatment allo-
cation.
Participants' data were monitored for departures from the normal
range, side effects and adverse events as well as study outcomes. Day to
day management was coordinated under the direction of the Chief
Investigator. Oversight of the study was provided by an Advisory
Committee and all adverse events were reportable to a Data
Management Safety Committee. All data collection sheets were sent by
airmail and fax to an independent data management unit, the Clinical
Informatics and Data Management Unit, Department of Epidemiology
and Preventive Medicine, Monash University.
A withdrawal was defined as an early exit that was not an outcome
of interest. This occurred either when a participant was excluded by the
Chief Investigator on grounds of medical safety or serious breach of trial
protocol, or, when a participant withdrew their consent, becoming “lost
to follow-up”.
2.3. Outcome event variables
The composite primary, clinical outcome was defined as hyperten-
sion (BP > 140/90mm Hg) and/or albuminuria, ACR≥3.4 mg/mmol,
and/or HbA1c>6.5%, all these components were confirmed by one or
two subsequent tests. Secondary outcomes were cardiovascular events,
including myocardial infarction, cerebral or coronary ischaemic events
and peripheral vascular events, including natural cardiovascular death.
The trial was powered to detect a 50% reduction in the number of
primary outcome events with a treatment duration of up to 5 years, a
25% withdrawal rate and at least 114 people in each treatment arm.
Calculations drew upon on the findings of the 2004–2006 health screen
conducted in the same community in which 55% of adults, or about 600
people meeting the study eligibility criteria, had 5.5–11.2% annual
incidence rates of the primary outcome (unpublished data). A minimum
sample size requirement for the study was based upon the numbers of
people having events in these earlier studies.
2.4. Statistical analysis
Analyses were conducted using Stata 14 software [StataCorp. 2015.
Stata Statistical Software: Release 14. College Station, TX: StataCorp LP].
One hundred and twenty-five eligible participants who commenced
treatment were included in analyses, utilising a modified intention-to-
treat principle. Participants excluded from analyses (44/169) were
those who did not commence treatment or those in whom ineligibility
became apparent after randomisation.
Mean (SD), geometric mean (95%CI) or proportions were used to
summarise variables. Group differences in continuous variables were
tested with a t-test where variances were equal and distributions ap-
proximated normal, or a rank-sum test. A chi2 test was used for
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categorical variables. Skewed continuous variables were assessed using
natural and log transformed versions.
Analyses were designed to assess the categorical combined outcome
event. Survival time to event analyses were performed to estimate
outcome incidence, and Kaplan–Meier survivor functions were tested
for equality, using the log-rank test. Despite the intention to report Cox
proportional hazard analyses, accounting for baseline age and or sex, it
was not possible due to an insufficiency of outcome events. Analyses
also examined the distributions of BP, ACR and HbA1c, as continuous
variables.
The changes in systolic blood pressure (SBP), diastolic blood pres-
sure (DBP), ACR and HbA1c were modelled with multilevel mixed-ef-
fects linear regression. Graphical representations of time-related trends
in events were also inspected with locally weighted scatterplot
smoothing (Lowess models) to assess the linearity of the relationships of
outcome measures to time. All models were assessed with and without
adjustment for combinations of the variables sex, baseline age and
various degrees of treatment adherence. Those presented restrict
follow-up time up to the first 36 months (including exits), so that group
numbers were more robust.
3. Results
One hundred and sixty nine adults, 127 (75%) men and 42 women
(25%), were randomised. Analyses were conducted on 125 participants
(60 ACEi, 65 Placebo), after the exclusion of 44 who either took no
treatment (n=41), principally for reasons related to competitive
football, drug and or alcohol use, mental health issues, voluntary or
enforced absence from the community and lack of interest, or were
falsely enrolled (n=3), whose ineligibility became apparent after
randomisation. The analysis group did not differ significantly by age,
sex or randomisation to treatment arm, from those excluded (A 1).
There was an apparent imbalance in females allocated to the treatment
arms (ACEi/placebo), with 10/17 and 10/5 females in the analysis and
non-analysis groups respectively (p=0.065).
Baseline demographic, clinical and biochemical characteristics of
the analysis group by treatment arm, are shown in Table 1. There were
no significant differences.
The median length of an individual's participation was 2.5 years
(0.08–4.25 years) in the ACEi arm and 3.0 years (0.08–4.27 years) in
the placebo arm, they were not significantly different (p= 0.763).
Sixty-five persons (52%) participated up to 3 years, 33 (26%) partici-
pated up to 1 year and 11 (8%) participated up to 3 months (not
shown). Total person time on treatment was 138.7 person-years in the
ACEi arm and 155.4 person-years in the placebo arm, an overall total of
294.1 years. Participation time did not differ by sex (p= 0.600),
however, 7% (n= 9) of women were enrolled late in the trial.
(Enrollment numbers at specified follow-up time points and a summary
of follow-up time, by treatment arm and sex, are shown in A 2a and b).
Adherence to the tablet regimen was variable, however; 73.3% (44/60)
of participants in the ACEi arm took, on average, at least 50% of
Table 1
Baseline characteristics, n-125 disease free adults, by treatment arm: Primary Prevention Trial, 2008–2013.
Characteristic ACEi N=60 Placebo N=65 P
Age, years; G mean (95% CI) 31.7 (29.6–33.9) 31.9 (29.7–34.1) 0.909
Sex; (M/F) 50/10 48/17 0.198
SBP, mm Hg (mean, SD) 114.8 (11.0) 113 (10.2) 0.475
DBP, mm Hg (median, IQR) 73.0 (7.6) 72.5 (9.1) 0.705
HbA1c, % (mean, SD) 5.7 (0.2) n=59 5.7 (0.2) n= 64 0.955
ACR, mg/mmol; G mean (95% CI) 0.61 (0.51–0.74) 0.76 (0.63–0.92) 0.116
Weight, kg; G mean (95%CI) 61.0 (57.8–64.3) n= 49 62.0 (59.0–65.10) n= 55 0.116
Waist circumference, cms; median, IQR 80.0 (74.0–91.0) n= 49 80.3 (74.3–90.0) n=52 0.954
Cholesterol, mmol/L; mean, SD 5.1 (0.8) n=60 4.9 (0.9) n= 63 0.422
HDL, mmol/L; median, IQR 1.2 (1.1–1.4) n= 60 1.2 (1.0–1.4) n=63 0.326
LDL, mmol/L; mean, SD 3.1 (0.8) n=59 3.1 (0.8) n= 63 0.788
Triglycerides, mmol/g; G mean (95% CI) 1.4 (1.2–1.7) n= 60 1.2 (1.1–1.4) n=63 0.068 0.223 rsum
Note: P= t-test, ranksum or chi2, SD= standard deviation, IQR= inter-quartile range, ACR=albumin creatinine ratio, SBP= systolic blood pressure,
DBP=diastolic blood pressure, G mean= geometric mean.
Table 2
Frequencies of primary and secondary outcome events, by category and treat-
ment arm: Primary Prevention Trial, 2008–2013.
Outcome ACEi
N=60
Placebo
N=65
Primary
Diabetes 0 4
Hypertension 0 1
Elevated ACR 5 3
Secondary
Cardiovascular event 1 2
Total 6 (10%) 10 (15.4%)
Note: Elevated ACR=albumin creatinine ratio ≥3.4 mg/mmol; represents 16
events among 15 people, a combined elevated ACR and diabetes outcome oc-
curred in one person in the placebo arm.
Table 3A
Incidence rates of outcomes per event by treatment arm: Primary Prevention
Trial females, 2008–2013.
Outcome ACEi
N=10 FU: 17.3 py
Placebo
N=18 FU: 45 py
P rates ACEi vs
placebo
# events; rate (CI)
per 100 py
# events; rate (CI) per
100 py
Diabetes 0; 0 3; 6.7 (2.2–20.7) 0.382
Hypertension 0; 0 0; 0 NA
Elevated ACR 0; 0 1; 2.2 (0.3–15.8) 0.547
Cardiovascular 0; 0 1; 2.2 (0.3–15.8) 0.706
Non-ACR 0; 0 4; 8.9 (3.3–23.7) 0.342
Any/all 0; 0 5; 11.1 (4.6 – 26.7) 0.251
Table 3B
Incidence rates of outcomes per event by treatment arm: Primary Prevention
Trial males, 2008–2013.
Outcome ACEi
N=50 FU: 121.4 py
Placebo
N=48 FU: 112.7 py
P rates ACEi vs
placebo
# events; rate (CI)
per 100 py
# events; rates (CI)
per 100 py
Diabetes 0; 0 1; 0.9 (0.1–6.3) 0.289
Hypertension 0; 0 1; 0.9 (0.1–6.3) 0.239
Elevated ACR 5; 4.1 (1.7–9.9) 2; 1.8 (0.5–7.1) 0.283
Cardiovascular 1; 0.8 (0.1–5.9) 1; 0.9 (0.1–6.3) 0.950
Non-ACR 1; 0.8 (0.1–5.9) 3; 2.7 (0.9–8.3) 0.246
Any/all 6; 4.9 (2.2 – 11.0) 5; 4.4 (1.9– 10.7) 0.873
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allocated treatment. There was no difference by sex; 70% of females (7/
10) and 73% of males (44/60) had adherence of ≥50% (p= 0.548).
Fifty-nine participants (47%) withdrew from the trial prior to clo-
seout for reasons other than a primary or secondary outcome of in-
terest. Forty-seven participants (38%) were lost to follow-up, which
commonly occurred when participants moved to another location,
planned a pregnancy or played sport at an elite level. Three people
(2.4%), all in the placebo arm, had a serious adverse event. None of
these events was found to have a relationship to potential pharmaco-
logical toxicity, but they did result from study participation, and led to
exclusion from the trial. Nine additional people (7%) were withdrawn
due to the onset of medical conditions, all of which were clearly un-
related to study treatment. Six people had serious adverse events that
did not necessitate withdrawal. There was no difference in the fre-
quency of any of these categories by treatment arm. A 3a-b summarises
the withdrawals by treatment arm and further describes the adverse
events.
Sixteen primary or secondary outcomes of interest occurred among
15 participants (Table 2). Six people in the ACEi arm, all males, had 6
events (10% of participants), and the nine people in the placebo arm
had 10 events (15.2% of participants). Specifically, 5 people in the ACEi
arm developed elevated ACR and one developed myocardial infarction,
while in the placebo arm, 4 developed diabetes, 1 hypertension, 3
elevated ACR, 1 myocardial infarction and 1 myocardial ischaemic
event, with one of these people (a female) developing both diabetes and
elevated ACR. All outcomes in the ACEi arm (all amongst males) were
among people with adherence of at least 50% of allocated treatment.
Notably, no females among 10 in the ACEi arm developed any
outcomes (0%), while 5 among 17 in the placebo arm (29.4%) did.
There was a trend towards higher numbers of all other outcomes in
the Placebo arm, with the exception of elevated ACR. We also examined
the outcomes by treatment arm over time (provided in A 4); however,
no persuasive pattern of difference emerged.
Incidence rates (unadjusted) for the outcome events, per 100
person-years, in females, males and females, and males together, are
presented in Table 3A–C. Notably, the absolute incidence rates in the
placebo group, and the 2-fold differences between males and females,
are entirely compatible with the (unpublished) data collected in the
natural history phase on which the sample size for this trial was ori-
ginally estimated.
The tables show that diabetes, hypertension and secondary outcome
events were more common in the placebo arm in both females and
males (3A,B). In combination, these “non-ACR” events occurred at a
rate of 0.7 (0.1–5.1) per 100 person-years in the ACEi arm, and at a rate
of 4.4 (2.1–9.3) per 100 person-years in the placebo arm (3C). The
difference in these rates approached significance (P= 0.060). There
was also a higher, although non-significant (p=0.500), rate of a
combined event of all primary and secondary outcomes in the placebo
arm among all participants (3C). None of the ten females in the ACEi
arm experienced any event (0%), in contrast to 5 out of 17 females
(28%) in the placebo arm, at a rate of 11.1 (4.6–26.7) per 100 person-
years: however, the difference was not significant (P= 0.251) (3A).
Kaplan-Meier survival curves of the outcome events combined, by
treatment arm, in females, males, and females and males together
(Fig. 1A–C), highlight the wider discrepancy in the female rather than
the male rates.
Cox proportional hazards models for a combined outcome event in
all participants suggested a lower rate of events in the ACEi arm, al-
though non-significant (not shown). It was not possible to derive esti-
mates for females separately as there were no events among females in
the ACEi arm.
Changes over time (up to 36 months of follow-up) in the outcome
measures of HbA1c, ACR, SBP and DBP, without additional adjustment
or exclusion of outlying values, are summarised in A 5. In females there
was no significant difference between the ACEi and placebo arms for
any of these outcomes, however, they all, particularly ACR, had a non-
significant tendency to be at a lower level in the ACEi arm.
Males in the treatment arm showed no benefit for HbA1c, and a non-
significant trend towards benefit in SBP.
Adjustment for age at randomisation did not alter any findings.
Lowess modelling, without adjustment (see Fig. 2A–H), lends sup-
port to these findings and indicates that the relationships may not be
linear.
4. Discussion
This was the first randomised controlled trial of pharmaceutical
prevention of albuminuria, hypertension or diabetes in the setting of a
high-risk remote-living Australian Aboriginal group. It was conducted
Table 3C
Incidence rates of outcomes per event by treatment arm: Primary Prevention
Trial females and males, 2008–2013.
Outcome ACEi
N=60 FU: 138.7
py
Placebo
N=66 FU: 157.7 py
P rates ACEi vs
placebo
# events; rate (CI)
per 100 py
# events; rate (CI)
per 100 py
Diabetes 0; 0 4; 2.5 (1.0–6.8) 0.072
Hypertension 0; 0 1; 0.6 (0.09–4.5) 0.330
Elevated ACR 5; 3.6 (1.5–8.7) 3; 1.9 (0.6–5.9) 0.357
Cardiovascular 1; 0.7 (0.1–5.1) 2; 1.3 (0.3–5.1) 0.670
Non-ACR 1; 0.7 (0.1–5.1) 7; 4.4 (2.1–9.3) 0.060
Any/all 6; 4.3 (1.9 – 9.6) 10; 6.3 (3.4 -11.8) 0.500
Note: ACEi, angiotensin converting enzyme inhibitor; P, log-rank tests of
equality calculated from Kaplan-Meier survival functions (unadjusted); FU,
follow-up period; py, person-years; CI, 95% confidence interval; #, number;
ACR, albumin creatinine ratio mg/mmol.
Fig. 1. A–C. Kaplan-Meier survival curves of all events by treatment arm and sex: Primary Prevention Trial, 2008-2013
Note: ACEi, angiotensin converting enzyme inhibitor; P, log-rank tests of equality calculated from Kaplan-Meier survival functions (unadjusted).
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Fig. 2. A–H., HbA1c, ACR, SBP and DBP levels over time, by sex, and treatment group: Primary Prevention Trial, 2008-2013
Note: Graphs show locally weighted scatterplot smoothing of unadjusted estimates for the period of up to the 36 month of follow-up; HbA1c, glycosylated hae-
moglobin A 1c; ACR, albumin creatinine ratio; SBP, systolic blood pressure (mm/Hg); DBP, diastolic blood pressure (mm/Hg).
W.E. Hoy et al. Contemporary Clinical Trials Communications 14 (2019) 100323
5
in a very challenging environment with multiple logistic hurdles.
Delayed ethics approval for commencement of the trial led to a
prolonged recruitment period in which the pool of potentially eligible
participants was reduced by new incidence of interim disease, reflecting
the high rates of disease experienced by the community. Additionally,
numbers of enrolled females were lower than anticipated, due to delay
of approval for the enrolment of fertile women who were using long-
term contraception, until the final two years of the trial. In remote
settings Aboriginal women, compared to men, have higher levels of
elevated ACR and higher incidence of new onset ACR up through early
adult life [12] and females also have significantly higher levels of end
stage kidney disease leading to RRT [13,14]. Exclusion of potentially
fertile women at the outset of the trial (and the inference that they were
not capable of managing their own fertility) created a negativity to-
wards the trial in both sexes, and contributed to the high withdrawal
rate of 47%, which was higher than the estimate of 25% used in power
calculations. The recruitment goal of≥114 people in each arm was not
achieved. Based upon the minimum requirement, and among those
analysed, there was a 14% deficit in male and a 76% deficit in female
enrolment.
Analyses were stymied by their lack of power, related to the small
unbalanced numbers of participants and outcomes, as well as to re-
cruitment biases and considerable periods of poor quality adherence
data. Field Staff reported instances of periodic medicine supply failure
due to weather events and tablet production problems, potential par-
ticipant awareness of their randomisation due to cosmetic differences in
tablets, and questionable accuracy of returned tablet count registra-
tions.
Elevated ACR was the most frequent outcome, but it was not sig-
nificantly more frequent in the placebo than the treatment arm. A
possible treatment benefit in terms of a combined diabetes, hyperten-
sion outcome, and, arguably, on cardiovascular events, however, does
lend support to our hypothesis, as do the observed tendencies for lower
SBP and HbA1c in the ACEi arm during follow-up. In 2001 the HOPE
study reported that new onset of diabetes, using elevated HbA1c as the
diagnostic marker, was reduced in individuals taking the ACEi,
Ramipril, compared to those on Placebo [15].
5. Conclusion
We present a catalogue of events describing an RCT of ACEi in a
remote Aboriginal Australian community. There was sub-optimal re-
cruitment, a gender imbalance, a small sample size, and subsequent
difficulty in interpreting the data. Nonetheless, there was a suggestion
of benefit of ACEi in females for all endpoints, and a trend towards
benefit on non-ACR endpoints when both sexes were examined to-
gether. In view of the huge burden of chronic disease in these com-
munities, consideration should be given to repeating some aspects of
such a trial under better conditions.
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